Cardiovascular toxic manifestations with the use of antimonials in a patient with cutaneous leishmaniasis

Main Article Content

Adrián Valverde Legarda
Marie Claire Berrouet

Abstract

Toxicity by antimonials has multiple systemic manifestations, including cardiovascular alteration, which is one of the most serious, as it can even lead to death of the patient. This article reports the case of an elderly patient who, during treatment with antimonials for cutaneous leishmaniasis, presented cardiac and hepatic toxicity associated with electrolyte imbalance as a perpetuating factor of her clinical condition, with subsequent development of multiple episodes of mono and polymorphic ventricular tachycardia. The patient was treated with synchronous and asynchronous defibrillation, overstimulation with pacemaker, and electrolyte replacement; she did not recover and eventually died. This report on the toxicity of antimonials is important as they remain the first-line treatment for leishmaniasis despite their multiple side effects, which can compromise multiple systems. Thus, health care professionals must become familiar with the early signs and symptoms of toxicity.

Keywords:
toxicity, leishmania, arrhythmias, cardiac

References

Vélez D, Hendrickx E, Robledo SM, Agudelo SP. Leishmaniosis cutánea en Colombia y género. Cad Saúde Pública 2001; 17(1):171-180.

Gaitán H, Lasso G, Gaitán H. Leishmaniasis cutánea en la provincia del Magdalena Centro, Cundinamarca, Colombia. Una serie de casos. Universitas Medica 2017; 58(2):2015-2018.

Santamaría M, Soto B, Velásquez l, Casas J, Castaño V, Benito G, et al. Guía para la atención clínica integral del paciente con leishmaniasis. Minsalud 2010;129.

Nicolas G, Koury E, Osman D, Salibi C, Nehme L, Mitri S, et al. Leishmania in a patient with small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Case Rep 2018; 19:512516.

Vélez JD, Carrillo DC. Leishmaniasis cutánea y anfotericina B liposomal. Reporte de caso. Infectio 2013; 17(4):201-204.

OPS. Leishmaniasis en las Américas: recomendaciones para el tratamiento. 2013. 1-46 p.

Gamboa LF, Becerra JA. Cardiotoxicidad por antimoniales. Rev Salud Bosque. 2012; 2(2):69-74.

Henao HH, Osorio Y, Saravia NG, Gómez A, Travi B. Eficacia y toxicidad de los antimoniales pentavalentes (Glucantime y Pentostam) en un modelo animal de leishmaniasis cutánea americana: aplicación de la luminometría. Biomédica 2004; 24(4):393.

Masmoudi A, Maalej N, Mseddi M, Souissi A, Turki H, Boudaya S, et al. Glucantime® par voie parentérale : bénéfice versus toxicité. Médecine Mal Infect 2005; 35(1):42–45.

Luciani A, Sconza S, Civitella C, Guglielmini C. Evaluation of the cardiac toxicity of N-methylglucamine antimoniate in dogs with naturally occurring leishmaniasis. Vet J 2013; 196(1):119-121.

Matoussi N, Ameur HB, Amor SB, Fitouri Z, Becher SB. Toxicité cardiaque de l’antimoniate de méglumine (Glucantime®). À propos d’une observation. Med Mal Infect 2007; 37(SUPPL. 3):257–259.

Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59(1):139-143.

Sadeghian G, Ziaei H, Sadeghi M. Electrocardiographic changes in patients with cutaneous leishmaniasis treated with systemic glucantime. Ann Acad Med Singapore 2008; 37(11):916-918.

Arcos L, Rincón C, Vanegas D, Medina R. Tormenta eléctrica y torsade de pointes asociados a tratamiento con antimoniales en un paciente con leishmaniasis cutánea. Rev Colomb Cardiol 2018; 9:5-9.

Edwards IR, Aronson JK. Adverse drug reactions Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356:1255-1259.

Baranwal AK, Mandal RN, Singh R, Singhi SC. Sodium stibogluconate and polymorphic ventricular tachycardia. Indian J Pediatr 2005; 72(3):269.

Villamañán E, Armada E, Ruano M. Prolongación del intervalo QT inducido por fármacos: ¿conocemos sus riesgos? Med Clin (Barc) 2015; 144(6):269-274.

Pérez-Riera AR, Barbosa-Barros R, Daminello R, da Costa de Rezende Barbosa MP, Esposito IC, de Abreu LC. The congenital long QT syndrome Type 3: An update. Indian Pacing Electrophysiol J 2018; 18(1):25-35.

Cay S, Ozeke O, Ozcan F, Topaloglu S, Aras D. Long QT: A syndrome or acquired finding? Pacing Clin Electrophysiol 2018; doi: 10.1111/pace.13357.

El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol 2018; 41(4):414-421.

Álvarez HPE. Causalidad en medicina. Gac Med Mex 2004; 140(4):467-472.

Invima. Boletín de farmacovigilancia [Internet]. La causalidad en farmacovigilancia. 2004. p. 1–10. Available from: https://www.invima.gov.co/images/stories/boletines/Boletin_5.pdf

Most read articles by the same author(s)